FR EA

Contract analysis

Clause-by-clause risk read on any document of the firm. Pick a contract, or open any document from a matter.

Contract analysis / closing-checklist.xlsx
closing-checklist.xlsx
1013-00002 · 5 clauses
High · 1 Medium · 1 Standard · 1
I. TRANSACTION DOCUMENTS High
⚑ Non-compete / exclusivity restraint
I. TRANSACTION DOCUMENTS 1.1 | Transaction Documents | Note Purchase Agreement (execution version), dated April 9, 2024, among Genome Dx Therapeutics Inc. (Issuer) and Pinnacle BioVentures Fund III, L.P., Cormorant Health Capital Partners, L.P., and Alder Creek Life Sciences Fund II, L.P. (Purchasers) — aggregate principal amount $40,000,000 | Calderwood & Harkness LLP / All Parties | April 9, 2024 | April 9, 2024 |
II. COMPANY CLOSING DELIVERABLES
II. COMPANY CLOSING DELIVERABLES 2.1 | Company Deliverables | Written Consent of the Board of Directors of Genome Dx Therapeutics Inc., dated April 5, 2024, approving issuance of the Notes and authorizing execution and delivery of NPA and ancillary documents | GenomeDx / Calderwood & Harkness LLP | April 5, 2024 | April 5, 2024 | Complete | Jonathan Merriweather (Board Chair / Managing Director, Pinnacle BioVentures)
III. PURCHASER CLOSING DELIVERABLES
III. PURCHASER CLOSING DELIVERABLES 3.1 | Purchaser Deliverables | Executed Signature Pages — Pinnacle BioVentures Fund III, L.P. to Note Purchase Agreement | Pinnacle BioVentures (Jonathan Merriweather, Managing Director, signing on behalf of Pinnacle BioVentures Management III, LLC, its General Partner) | April 22, 2024 | April 22, 2024 | Complete 3.2 | Purchaser Deliverables | Executed Signature Pages — Cormorant
IV. THIRD-PARTY / COUNSEL DELIVERABLES Standard
⚑ Commercial term
IV. THIRD-PARTY / COUNSEL DELIVERABLES 4.1 | Counsel Deliverables | Legal Opinion of Calderwood & Harkness LLP (Issuer's Counsel), dated April 22, 2024, addressed to all Purchasers | Calderwood & Harkness LLP (Theodore Langston) | April 22, 2024 | April 22, 2024 | Complete | Covers: due organization and good standing (DE and CA); corporate power and authority; due authorization, execution, and delivery; enforceabilit
V. POST-CLOSING ITEMS Medium
⚑ Notice / time limit to track
V. POST-CLOSING ITEMS 5.1 | Post-Closing | Form D filing with the SEC (within 15 days of first sale of securities) | Calderwood & Harkness LLP | May 7, 2024 (deadline) | April 24, 2024 | Complete | Filed April 24, 2024; first sale date April 22, 2024 5.2 | Post-Closing | Blue Sky Filing — California (Section 25102(f) notice) | Calderwood & Harkness LLP | Promptly after closing | April 25, 2024 | Complete 5.3 | Post-C